Navigation Links
PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
Date:4/12/2012

ements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, at this point there can be no assurance that PharmAthene's rPA product candidate will be shown to be safe and effective and approved by regulatory authorities for use in humans.  Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
4. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
5. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
6. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
7. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
8. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
9. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
10. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
11. PharmAthene Completes $6.5 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that executives from the company ... of September.  , Pedro Lichtinger ... Renshaw,s 17th Annual Global Investment Conference on Wednesday, September ... Regis Hotel in New York City ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, ... second US laboratory is to open in Manhattan, Kansas in early October, 2015. ... long-term growth of research and development through collaboration with researchers from Kansas State ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... PRINCETON, N.J., Aug. 30 Medarex, Inc.,(Nasdaq: MEDX ... at the,Thomas Weisel Partners Healthcare Conference at 11:30 AM ... being held at the Four,Seasons Hotel in Boston, Massachusetts. ... for replay through the Webcast page in,the Investor Relations ...
... 30 Micromet, Inc.,(Nasdaq: MITI ), a ... antibody-based products for cancer, inflammation and,autoimmune diseases, today ... Officer of Micromet, will present at the Sal. ... Wednesday,September 5, 2007 at 9:50am Eastern time (3:50pm ...
... Mass., Aug. 29 Insulet Corporation,(Nasdaq: PODD ... Insulin,Management System, today announced that Duane DeSisto, Chief ... Healthcare,Conference. Mr. DeSisto is scheduled to present an ... on September 6, 2007 at The Four Seasons ...
Cached Biology Technology:Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007 2Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference 2
(Date:8/12/2015)... SPRINGS, Florida , August 12, 2015 ... the pace of mobile payment innovation and advanced biometrics ... to replace the way consumers rely on using their ... ahead with reinventing the future for payment services led ... (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a prominent smartphone manufacturer in ... selected FPC1 155 for ...
(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... virus in tissues from patients who died of a ... the strain of virus in the measles vaccine caused ... issue of The Journal of Infectious Diseases, now available ... many more cases of the disease, known as subacute ...
... emitted about as much carbon monoxide as did human-related ... time period, according to new research by the National ... atmospheric concentrations of ground-level ozone across much of the ... extent to which wildfires contribute to atmospheric pollution, was ...
... Abuse Deaths (np-SAD) based at the International Centre for Drug ... has been a decline in the number of drug-related deaths ... drop of eight per cent. The report published today ... by Coroners and Procurators Fiscal in the UK and Islands ...
Cached Biology News:New study shows measles immunization may prevent fatal brain infection 2NCAR analysis shows widespread pollution from 2004 wildfires 2Continued reduction in the number of drug-related deaths in the UK 2Continued reduction in the number of drug-related deaths in the UK 3
... Ek Adaptor encodes a T7 promoter, ... ATG translation initation codon, and an N-terminal ... 109 aa sequence that encodes thioredoxin. Fusion ... enhance solubility of many proteins that are ...
...
The LIC Duet™ Mini Adaptor encodes a T7 promoter, lac operator, ribosome binding site (rbs), and an ATG translation initation codon. This adaptor is designed for expression of a target protei...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
Biology Products: